Lupin Limited has informed the stock exchanges that its Ankleshwar manufacturing facility in India has received a Form-483 from the U.S. FDA following a recent inspection. The pharmaceutical company disclosed this development in a regulatory filing dated March 07, 2026.

FDA Inspection Details

The U.S. FDA inspection at the Ankleshwar facility was conducted over a five-day period and concluded with specific regulatory observations.

Company Response and Commitment

Lupin has outlined its approach to addressing the FDA's findings and maintaining regulatory compliance. The company stated it will respond to the U.S. FDA within the stipulated timeframe to address the observations noted during the inspection.

The pharmaceutical manufacturer emphasized its commitment to maintaining Current Good Manufacturing Practice (CGMP) standards across all its facilities. This commitment reflects the company's focus on ensuring regulatory compliance and quality standards in its manufacturing operations.

Regulatory Disclosure

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer, and sent to both the National Stock Exchange of India Limited and BSE Limited.

Form-483 observations are issued by the FDA when inspectors identify conditions that may constitute violations of FDA regulations during facility inspections. Companies typically have a specified timeframe to respond with corrective actions and preventive measures.

Lupin Limited has successfully concluded GST Department inspection and search proceedings at its registered office with no adverse findings reported. The pharmaceutical company informed stock exchanges about the completion of the inspection that was initiated on February 25, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Department Inspection Details

The inspection was conducted by the Assistant Commissioner of State Tax, Maharashtra under Section 67 of Maharashtra Goods & Service Tax Act, 2017. The proceedings were carried out at the company's registered office located at Kalpaturu Inspire, Off W. E. Highway, Santacruz (East), Mumbai.

Inspection Outcome and Company Response

The GST Department Maharashtra concluded their inspection and search proceedings on March 2, 2026 at 8:15 p.m. (IST). Lupin provided complete cooperation throughout the inspection period, furnishing all necessary information and documents as requested by the authorities. The company's disclosure confirms that no official communication regarding any adverse findings has been issued by the GST Department.

Financial Impact Assessment

According to Lupin's official disclosure to stock exchanges, the conclusion of the inspection and search proceedings has no impact on the company's financials. The inspection was characterized as routine proceedings focused on documentation related to GST compliance and input tax credit claims. The absence of adverse findings validates the company's tax compliance practices.

Regulatory Compliance and Disclosure

The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as mandated under SEBI Listing Regulations. Company Secretary and Compliance Officer Amit Kumar Gupta digitally signed the disclosure document on March 2, 2026, ensuring full regulatory compliance and transparency with stakeholders.